Literature DB >> 9287323

The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand.

F S Monteclaro1, I F Charo.   

Abstract

High affinity binding of monocyte chemoattractant protein 1 (MCP-1) requires the presence of the amino-terminal domain of CCR2, the MCP-1 receptor. Here we report that the 35 amino-terminal residues of CCR2, expressed as a membrane-bound fusion protein, bound MCP-1 with an affinity similar to that of the intact, wild-type receptor. Furthermore, the amino-terminal fusion protein enhanced, in trans, agonist-dependent activation of a CCR2 variant that was engineered to lack the high affinity binding sites for MCP-1. Mutation of highly conserved cysteines in the amino-terminal domain and third extracellular loop of CCR2, but not in the fusion protein, resulted in a dramatic loss of MCP-1 binding, suggesting the existence of a critical intramolecular disulfide bond that positions the amino-terminal protein for ligand interaction. These data indicate that the amino-terminal region of CCR2 is both necessary and sufficient for the high affinity binding of MCP-1 and provide the first direct evidence for activation of a chemokine receptor by a pseudo-tethered ligand. In this model, high affinity binding by the relatively short amino-terminal domain of CCR2 serves to tether MCP-1 and enhance low affinity interactions with distal regions of the receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287323     DOI: 10.1074/jbc.272.37.23186

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus.

Authors:  A Carfí; C A Smith; P J Smolak; J McGrew; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement.

Authors:  Michael B Deci; Scott W Ferguson; Sydney L Scatigno; Juliane Nguyen
Journal:  Mol Pharm       Date:  2018-06-04       Impact factor: 4.939

3.  Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma.

Authors:  K H Han; M K Chang; A Boullier; S R Green; A Li; C K Glass; O Quehenberger
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 4.  Role of CCR2 in inflammatory conditions of the central nervous system.

Authors:  Hannah X Chu; Thiruma V Arumugam; Mathias Gelderblom; Tim Magnus; Grant R Drummond; Christopher G Sobey
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-02       Impact factor: 6.200

5.  Structure of monomeric Interleukin-8 and its interactions with the N-terminal Binding Site-I of CXCR1 by solution NMR spectroscopy.

Authors:  Sabrina Berkamp; Sang Ho Park; Anna A De Angelis; Francesca M Marassi; Stanley J Opella
Journal:  J Biomol NMR       Date:  2017-11-15       Impact factor: 2.835

Review 6.  New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Authors:  Andrew B Kleist; Anthony E Getschman; Joshua J Ziarek; Amanda M Nevins; Pierre-Arnaud Gauthier; Andy Chevigné; Martyna Szpakowska; Brian F Volkman
Journal:  Biochem Pharmacol       Date:  2016-04-19       Impact factor: 5.858

7.  The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2.

Authors:  J M Rodríguez-Frade; A J Vila-Coro; A M de Ana; J P Albar; C Martínez-A; M Mellado
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

8.  Epstein-Barr virus (EBV)-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium.

Authors:  Sharof Tugizov; Rossana Herrera; Piri Veluppillai; John Greenspan; Deborah Greenspan; Joel M Palefsky
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

9.  Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1).

Authors:  Joshua H Y Tan; Meritxell Canals; Justin P Ludeman; Jamie Wedderburn; Christopher Boston; Stephen J Butler; Ann Marie Carrick; Todd R Parody; Deni Taleski; Arthur Christopoulos; Richard J Payne; Martin J Stone
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

10.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.